pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·1h ago·1 min read
save

Health insurance premiums surge as CMS ramps up Medicaid fraud crackdown

Oct 26, 2026·read at STAT ↗RegulatoryNegative

Premiums for health insurance are climbing sharply, putting pressure on both large and small employers. While many firms have absorbed the cost to stay competitive, smaller businesses are beginning to feel the strain.

The latest Medicaid enrollment data show a decline, reflecting the growing financial burden on low‑income patients. This trend highlights broader concerns about access to affordable care.

At the same time, the Centers for Medicare & Medicaid Services announced a new initiative to intensify fraud detection and enforcement. The crackdown aims to recover improper payments and deter future abuse, adding another layer of complexity for providers and insurers.

Industry observers note that rising costs and regulatory actions could reshape how health‑care companies negotiate contracts and manage risk, with potential ripple effects across the pharmaceutical sector.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Rising premiums, a sad Medicaid gathering, and a new fraud crackdown”

read at STAT ↗
503 words · retrieved 29m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Protara Therapeutics, Inc.8RISING3
topics
Oncology2Vaccine

related stories

  • Oct 13Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earningsBioSpace
  • Oct 1Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEOFierce Biotech
  • Sep 30Rural MAHA followers say Trump hasn’t improved health of their communities, poll findsSTAT
  • Sep 22New federal autism committee head has financial ties to leucovorinSTAT
  • Sep 15Businesses can now apply for NIH fundingSTAT